The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Antibody Drug Conjugates Market (6th Edition) by Indication (Breast cancer, Blood cancer, Colorectal cancer, Gastric cancer, Gynecological cancer, Head and neck cancer, Lung cancer and Others), Linker (VC, Sulfo-SPDB, VA, Hydrazone and Others), Payload (MMAE, DM4, Camptothecin, DM1, MMAF, and Others), Target Antigens (CD30, HER2, CD22, CD33 and Others) and Geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    August 2021

  • Pages
    630

  • View Count
    20201

Example Insights

Antibody-Drug-Conjugates-Market-Context Antibody-Drug-Conjugates-Market-Contemporary-Trends Antibody-Drug-Conjugates-Market-Development-Pipeline Antibody-Drug-Conjugates-Market-Distribution-by-Payload-Type
Antibody-Drug-Conjugates-Market-Patent-Analysis Antibody-Drug-Conjugates-Market-Funding-and-Investment Antibody-Drug-Conjugates-Market-Key-Biological-Targets Antibody-Drug-Conjugates-Market-Key-Opinion-Leaders
Antibody-Drug-Conjugates-Market-Parnerships-and-Collaborations Antibody-Drug-Conjugates-Market-Combination-Therapies Antibody-Drug-Conjugates-Market-Clinical-Research-Landscape Antibody-Drug-Conjugates-Market-Key-Commercialization-Strategies
Antibody-Drug-Conjugates-Market-Distribution-by-Companies-by-ADC-Manfacturing-Service-Offered Antibody-Drug-Conjugates-Market-Promotional-Strategies Antibody-Drug-Conjugates-Market-Distribution-by-Indications Antibody-Drug-Conjugates-Market-Future-Forecast

 

Overview

We are aware that various second and third generation ADCs that are being developed by different companies, have shown significant improvements, in terms of clinical results, compared to traditional ADCs. As a result, novel ADC technologies have garnered the attention of physicians, patients and their families, having demonstrated improved clinical outcomes. We are optimistic about the growth of the ADCs market and believe that competition in this domain is likely to increase in the future.

- Executive Director / Chief Innovation Officer, a big pharma company

Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates (ADCs) to be recognized as potent therapies targeting a wide range of indications, including solid tumors and hematological malignancies. ADCs are engineered therapeutics comprised of monoclonal antibodies attached to potent cytotoxic payloads through chemical linkers. In fact, the FDA has approved 11 ADCs, namely ado-trastuzumab emtansine (Kadcyla®), brentuximab vedotin (Adcetris®), inotuzumab ozogamicin (Besponsa®), gemtuzumab ozogamicin (Mylotarg®), moxetumomab pasudotox (Lumoxiti®), polatuzumab vedotin-piiq (Polivy®), enfortumab vedotin (Padcev®), sacituzumab govitecan (Trodelvy®), trastuzumab deruxtecan (Enhertu®), belantamab mafodotin-blmf (Blenrep®), and loncastuximab tesirine-lpyl (Zynlonta™) till date. The success of these therapeutics can be attributed to their high tumor selectivity and cell-killing potential of monoclonal antibodies, while limiting off target toxicities. These advantages have made ADCs a new frontier of chemotherapy, thus, bringing about a paradigm shift in the treatment protocol of different types of cancer.

The growing popularity of ADCs is evident from the number of patents filed / granted for ADCs, which has increased from 1,992 in 2011 to over 22,700 in the first quarter of 2021. With approximately 80 ADCs being investigated in more than 250 clinical trials, the pharmaceutical industry is witnessing a dynamic shift from conventional technologies to newer and more robust approaches for the development of such complex biomolecules. In the past few years, several well-funded start-ups / small companies, offering advanced linker technologies, more potent warheads, and novel conjugation technologies, were established. Moreover, multiple licensing deals were inked in the past few years between various stakeholders, to advance the development of ADCs product pipeline. It is worth noting that companies are also evaluating their proprietary ADCs in combination with other effective therapeutic modalities, such as epigenetic modulator, immune checkpoint inhibitors, and monoclonal antibodies. ADC-based combination therapies offer multifaceted advantages, such as reduced drug resistance, improved drug efficacy, shrinking tumor metastasis, and increased cancer survival rates. In addition, novel conjugated drug molecules, such as bicycle drug conjugate (Bicycle Therapeutics), extracellular drug conjugate (Centrose), peptide conjugate (Esperance Pharmaceuticals), phospholipid drug conjugate (Cellectar Biosciences), radionucleotide conjugate (Nordic Nanovector), and tunable drug conjugate (BlinkBio) have also been introduced. Driven by the substantial progress in the use of novel ADC-based combination therapies, the associated clinical results, and ongoing technological advancement, coupled to the marketing authorization of multiple ADCs, the ADC therapeutics market is anticipated to grow at a commendable rate in the mid to long-term.

Scope of the Report

The “Antibody Drug Conjugates Market (6th Edition) by Target Indication (Breast cancer, Blood cancer, Colorectal cancer, Gastric cancer, Gynecological cancer, Head and neck cancer, Lung cancer, and Others), Type of Linker Used (VC, Sulfo-SPDB, VA, Hydrazone linker, and Others), Type of Payload (MMAE, DM4, Camptothecin, DM1, MMAF, and Others), Target Antigens (CD30, HER2, CD22, CD33, and Others), and Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current and future potential of ADCs being developed for the treatment of various indications. In addition, it features an elaborate discussion on the likely opportunity for the players engaged in this domain, over the next decade. Amongst other elements, the report includes:

  • A detailed review of the current market landscape of ADCs, providing information on drug developer(s) and technology provider(s), phase of development (marketed, phase III, phase II/III, phase II, phase I/II, phase I, preclinical / discovery stage) of lead candidates, target antigen (CD30, HER2, CD22, CD33, and Others), type of linker used (VC, Sulfo-SPDB, VA, Hydrazone linker, and Others), type of payload / warhead / cytotoxin (MMAE, DM4, Camptothecin, DM1, MMAF, and Others), type of antibody (Anti-HER2, Anti-TROP2, Anti-CD30, Anti-mesothelin, Anti-CD22, and Others), antibody isotype (IgG, IgG1, IgG2, and IgG4), type of therapy (monotherapy and combination therapy), combination drug(s) (if being evaluated as combination therapy), target indication(s) (breast cancer, blood cancer, colorectal cancer, gastric cancer, gynecological cancer, head and neck cancer, lung cancer, and others), line of treatment (1st line, 2nd line, 3rd line, and Others), route of administration (intravenous and subcutaneous), and dosing frequency (Q1 weeks, Q2 weeks, Q3 weeks, Q4 weeks, and Others).
  • Elaborate profiles of companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments, and an informed future outlook.
  • An analysis of the most commonly targeted therapeutic indications and details of ADC candidates being developed against them, highlighting key epidemiological facts about the diseases and currently available treatment options, other than ADCs.
  • A list of key opinion leaders (KOLs) within this domain, featuring detailed 2×2 matrices to assess the relative experience of the individuals, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field. It also includes a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers engaged in this domain. In addition, it presents an analysis assessing the credibility and (relative) level of expertise of different KOLs, based on number of publications, number of citations, number of clinical trials, number of affiliations, and strength of professional network (based on information available on LinkedIn).
  • An insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for ADC development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of clinical trials and number of target disease indications, and [B] a five-dimensional spider-web analysis, highlighting the most popular biological targets based on a number of relevant parameters, including affiliated publications, grants received to support research on a particular target, number of industry players involved in drug development efforts based on a singular target and geographical distribution of associated clinical trials. 
  • An analysis of the recent collaborations (since 2014) focused on the development of ADCs. It includes partnerships inked by various stakeholders in this domain, covering R&D collaborations, licensing agreements (specific to technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, mergers and acquisitions, and other relevant agreements. 
  • An analysis of the investments made, including seed funding, venture capital financing, debt funding, grants, capital raised from IPOs and subsequent offerings, at various stages of development, in companies that are focused on developing ADCs.
  • An in-depth analysis of the various patents that have been filed / granted related to ADCs. It includes information on key parameters, such as patent type, publication year, geographical location, issuing authority, assigned CPC symbol, emerging focus areas, and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
  • A study of the various grants that have been awarded to research institutes engaged in projects related to ADCs, between 2016 and 2021, highlighting various important parameters, such as year of award, support period, amount awarded, funding institute, grant type, focus area, type of recipient organization, key project leaders, key regions, and leading recipient organizations.
  • An in-depth analysis of completed, ongoing, and planned clinical studies of various ADCs, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target disease indication, and key geographical regions.
  • An elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch, during / post launch, including a timeline representation of the key strategies adopted by drug developers for the commercialization of their proprietary products.
  • An analysis of the key promotional strategies that have been adopted by the developers of marketed products, namely POLIVY™, LUMOXITI™, BESPONSA®, MYLOTARG™, KADCYLA® and ADCETRIS®.
  • An assessment of various therapeutics that are being evaluated in combination with ADCs. The study also presents the likely evolution of these therapeutics across different indications. 
  • A review of the evolution of ADC conjugation technologies, highlighting the various approaches that have been adopted across different generations; in addition, it presents a review of the existing competition between various conjugation approaches that are available / under development.
  • An overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection in ADCs. The study presents findings from various ADC studies in different animal models. It also includes an analysis of different methods used in estimating FIH doses. In addition, it highlights the possible FIH starting doses and estimated dose escalations required to reach human maximum tolerated dose (MTD).
  • An elaborate discussion on various factors that form the basis for the pricing of ADC products, featuring different models / approaches that pharmaceutical companies may choose to adopt while deciding the price of their respective lead therapy candidates that are likely to be marketed in the coming years.
  • A case study on manufacturing of ADCs, highlighting the key challenges, and a list of contract service providers that are involved in this domain.
  • A case study on companies offering companion diagnostics that can potentially be used to make treatment related decisions involving ADCs, providing information on the geographical location of key diagnostic developers, affiliated disease biomarkers, assay technique involved, target indication(s), the type of sample required (tumor tissue, blood, bone marrow and others) and the drug candidates for which a particular test was developed.
  • A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.

Key Questions Answered

  • Who are the leading players engaged in the development of ADCs?
  • Which indications can be treated with ADCs?
  • Which partnership models are commonly adopted by stakeholders in this domain?
  • What are the investment trends in this industry?
  • Which are the most active clinical trial centers?
  • Who are the key opinion leaders that can help you drive your development efforts?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current state of the market for ADCs and its likely evolution in the short-mid-term and long term.

Chapter 3 provides an introduction to ADCs, featuring brief description of ADCs, its components, mechanisms of action, and advantages over traditional targeted therapies. It also features a brief description of the absorption, distribution, metabolism and excretion (ADME) properties of various ADCs that are under development.

Chapter 4 provides information on 300 ADCs that are either approved or under development for the treatment of various indications. It features a detailed analysis of marketed / under development molecules, based on phase of development (marketed, phase III, Phase II/III, phase II, phase I/II, phase I, preclinical / discovery stage) of lead candidates, target antigen (CD30, HER2, CD22, CD33, and Others), type of linker used (VC, Sulfo-SPDB, VA, Hydrazone linker, and Others), type of payload / warhead / cytotoxin (MMAE, DM4, Camptothecin, DM1, MMAF, and Others), type of antibody (Anti-HER2, Anti-TROP2, Anti-CD30, Anti-mesothelin, Anti-CD22, and Others), antibody isotype (IgG, IgG1, IgG2, and IgG4), type of therapy (monotherapy and combination therapy), combination drug(s) (if being evaluated as combination therapy), target indication(s) (breast cancer, blood cancer, colorectal cancer, gastric cancer, gynecological cancer, head and neck cancer, lung cancer, and others), line of treatment (1st line, 2nd line, 3rd line, and Others), route of administration (intravenous and subcutaneous), and dosing frequency (Q1 weeks, Q2 weeks, Q3 weeks, Q4 weeks, and Others).

Chapter 5 presents elaborate profiles of companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios. Each profile features an overview of the company, its financial information (if available), product portfolio, recent developments, and an informed future outlook.

Chapter 6 provides information on the most commonly targeted therapeutic indications and features brief description of the ADC candidates being developed against them. It highlights the key epidemiological facts about the diseases and currently available treatment options, other than ADCs.

Chapter 7 provides an analysis of KOLs in the field of ADCs. It features a comprehensive list of principal investigators / study directors of different clinical trials, along with the information related to the affiliated research institutes. The chapter features a schematic representation on a world map, highlighting the geographical locations of eminent scientists / researchers who are engaged in clinical research in this domain. It also presents a comparative analysis, highlighting those KOLs who have relatively more experience in this domain. The credibility and (relative) level of expertise of different KOLs defined by other analysts / industry experts were compared to the results obtained using a proprietary scoring criteria, which was based on number of publications, number of citations, number of clinical trials, number of affiliations, and extent of professional network.

Chapter 8 presents an insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for ADC development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of clinical trials and number of target disease indications, and [B] a five-dimensional spider-web analysis, highlighting the most popular biological targets based on a number of relevant parameters, including affiliated publications, grants received to support research on a particular target, number of industry players involved drug development efforts based on a singular target and geographical distribution of associated clinical trials.

Chapter 9 features an elaborate discussion and analysis of the various partnerships and collaborations that have been inked between various stakeholder in the industry, since 2014. Further, the partnership activity in this domain has been analyzed on the basis of year of agreement / partnership, the type of partnership model (R&D collaborations, licensing agreements (specific to technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, mergers and acquisitions, and others), companies involved, and regional distribution of the collaborations.

Chapter 10 presents details on various investments received by various players engaged in the development of ADCs. It also includes an analysis of the funding instances that have taken place in the market, till July 2021, highlighting the growing interest of the venture capital community and other strategic investors within this market.

Chapter 11 provides an in-depth patent analysis, presenting an overview on the filed / granted patents related to ADCs. The analysis highlights key details and trends associated with these patents, including patent type, publication year, geographical location, issuing authority, assigned CPC symbol, emerging focus areas, and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 12 provides information on the various grants that were awarded to research institutes conducting projects related to ADCs, between 2016 and 2021. The analysis also highlights important parameters associated with grants, such as year of award, support period, amount awarded, funding institute, grant type, focus area, type of recipient organization, key project leaders, key regions and leading recipient organizations.

Chapter 13 provides a detailed analysis of completed, ongoing, and planned clinical studies of various ADCs, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target therapeutic area, and key geographical regions.

Chapter 14 presents an elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch and during / post launch. It also features an in-depth analysis and timeline representation of the key strategies adopted by drug developers for the commercialization of their proprietary products. In addition, it provides a general overview of the drugs considered for studying the strategies in detail.

Chapter 15 highlights the key promotional strategies that are being implemented by the developers of marketed products, including POLIVY™, LUMOXITI™, BESPONSA®, MYLOTARG™, KADCYLA®, and ADCETRIS®. The promotional aspects covered in the chapter include details provided on the product website (including key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 16 features an overview of the various therapeutics being evaluated in combination with ADCs. It also features a study of the likely evolution of these therapeutics across different therapeutic indications.

Chapter 17 provides a review of the evolution of ADC conjugation technologies, highlighting the various approaches that have been adopted across different generations. In addition, it presents a review of the existing competition between various conjugation approaches that are available / under development.

Chapter 18 provides an overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection. The chapter presents insights from recently conducted studies in different animal models, analyzing the different methods used in estimating FIH doses. In addition, it highlights possible FIH starting doses and estimated dose escalations required to reach human maximum tolerated dose (MTD). The chapter highlights different types of ADC-related toxicities observed in animal models, highlighting the doses at which these toxicities were observed.

Chapter 19 highlights our views on the various factors that must be taken into consideration while deciding the prices of ADC products. It features discussions on different models / approaches that pharmaceutical companies may choose to adopt while deciding the prices at which their ADC products can be marketed. 

Chapter 20 provides details of the players that offer contract manufacturing services for ADCs, or possess the necessary capabilities and infrastructure to manufacture such products in-house. The chapter illustrates the manufacturing capabilities of different contract manufacturers highlighting their expansion plans and other agreements inked between companies.

Chapter 21 is a case study focused on the use of companion diagnostics in the field of ADCs. It provides a list of companies offering companion diagnostics for targets being targeted by ADCs, including information on their geographical location, affiliated biomarker, assay technique involved, target indication(s), the type of sample required (tumor tissue, blood, bone marrow and others) and the drug candidate(s) for which it is already available.

Chapter 22 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the ADCs market within the biopharmaceutical industry, under a comprehensive SWOT framework.

Chapter 23 features an elaborate market forecast analysis, highlighting the likely growth of ADC market, till the year 2030. In order to provide details on future opportunity, our projections have been segmented on the basis of [A] target indication (Breast cancer, Blood cancer, Colorectal cancer, Gastric cancer, Gynecological cancer, Head and neck cancer, Lung cancer, and Others), [B] type of linker used (VC, Sulfo-SPDB, VA, Hydrazone linker, and Others), [C] type of payload (MMAE, DM4, Camptothecin, DM1, MMAF, and Others), [D] target antigens (CD30, HER2, CD22, CE33, and Others), and [E] key geographies (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.

Chapter 24 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented a brief overview of the companies and details of our conversations with Christian Rohlff, (Founder and Chief Executive Officer, Oxford BioTherapeutics), Paul Jaminet (Founder and Chief Executive Officer, Angiex), Sasha Koniev (Co-Founder and Chief Executive Officer, Syndivia), Aldo Braca (President and Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Senior Manager, BSP Pharmaceuticals), John Burt (Chief Executive Officer, Abzena), Michael Schopperle (Chief Executive Officer, CureMeta), Anonymous (Chief Executive Officer, Leading CMO), Jeff Landau (Chief Business Officer and Head of Strategy, CytomX), Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics), Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma), Toshimitsu Uenaka (Executive Director, Eisai) and Takashi Owa (Chief Innovation Officer, Eisai), Justin Oh (Executive Director, AbTis), Sukumar Sakamuri (Vice President and Head of Chemistry, AmbrX), Anonymous (Director, Business Development, Leading CMO), Anthony DeBoer (Director, Business Development, Synaffix), Christian Bailly (Director of CDMO, Pierre Fabre), Jennifer L. Mitcham (Director, SMARTag ADCs and Bioconjugates, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions), Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza), Mark Wright (Site Head, Piramal Healthcare), Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services), and Alan Burnett (Professor, School of Medicine, Cardiff University).

Chapter 25 is the summary of the overall report, which presents the insights on the contemporary market trends and the likely evolution of the ADC therapeutics market.

Chapter 26 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 27 is an appendix, which contains a list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Evolution of Anticancer Therapies 
3.3. Cancer Treatment Methods
3.3.1. Surgery
3.3.2. Radiation Therapy
3.3.3. Chemotherapy
3.3.4. Targeted Therapies

3.4. Monoclonal Antibody-Based Anticancer Therapies
3.5. Components of Antibody Drug Conjugates (ADCs)
3.5.1. Antibody
3.5.2. Cytotoxin
3.5.3. Linker

3.6. Advantages of ADC Therapeutics Over Traditional Therapeutic Interventions
3.7. Differences Between Small Molecule Drugs, Monoclonal Antibody-Based Therapies and ADCs
3.8. Pharmacokinetic Properties of ADCs
3.8.1. Absorption
3.8.2. Distribution
3.8.3. Metabolism and Elimination

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Antibody Drug Conjugates: Drug Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Target Disease Indication
4.2.3. Analysis by Line of Treatment
4.2.4. Analysis by Dosing Regimen
4.2.5. Analysis by Type of Therapy
4.2.6. Analysis by Target Antigen
4.2.7. Analysis by Antibody Origin
4.2.8. Analysis by Antibody Isotype
4.2.9. Analysis by Type of Linker
4.2.10. Analysis by Type of Payload / Warhead
4.2.11. Antibody Drug Conjugates: Distribution by Target Antigens and Target Disease Indications
4.2.12. Antibody Drug Conjugates Approved and Development Pipeline: Grid Analysis

4.3. Antibody Drug Conjugates: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Key Players: Analysis by Number of Therapies
4.3.5. Logo Landscape: Analysis by Target Disease Indication and Company Size
4.3.6. Technology Platforms
4.4. Novel Drug Conjugates

5. COMPANY AND DRUG PROFILES
5.1. Chapter Overview
5.2. Seagen
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Pipeline Overview
5.2.3.1. Adcetris
5.2.3.2. Padcev
5.2.3.3. HuMax-TF
5.2.3.4. SGN-LIVIA
5.2.4. Recent Developments and Future Outlook

5.3. Roche / Genentech
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Pipeline Overview
5.3.3.1. Kadcyla
5.3.3.2. Polivy
5.3.4. Recent Developments and Future Outlook

5.4. Pfizer
54.1. Company Overview
5.4.2. Financial Information
5.4.3. Pipeline Overview
5.4.3.1. Mylotarg
5.4.3.2. Besponsa
5.4.4. Recent Developments and Future Outlook

5.5. AstraZeneca
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Pipeline Overview
5.5.3.1. Enhertu
5.5.4. Recent Developments and Future Outlook

5.6. Astellas Pharma
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Pipeline Overview
5.6.4. Recent Developments and Future Outlook 

5.7. ImmunoGen
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Pipeline Overview
5.7.3.1. Mirvetuximab Soravtansine
5.7.4. Recent Developments and Future Outlook 

5.8. Daiichi Sankyo
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Pipeline Overview
5.8.3.1. Patritumab deruxtecan
5.8.3.2. Datopotamab deruxtecan
5.8.4. Recent Developments and Future Outlook

5.9. Gilead
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Pipeline Overview
5.9.3.1. Trodelvy
5.9.4. Recent Developments and Future Outlook

5.10. AbbVie
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. Pipeline Overview
5.10.3.1. Telisotuzumab vedotin
5.10.3.2. ABBV-3373
5.10.4. Recent Developments and Future Outlook

5.11. Bayer
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. Pipeline Overview
5.11.3.1. Anetumab ravtansine
5.11.4. Recent Developments and Future Outlook

5.12. RemeGen
5.12.1. Company Overview
5.12.2. Pipeline Overview
5.12.2.1. Disitamab vedotin
5.12.3. Recent Developments and Future Outlook

5.13. ADC Therapeutics
5.13.1. Company Overview
5.13.2. Pipeline Overview
5.13.2.1. Zynlonta
5.13.2.2. Camidanlumab tesirine
5.13.3. Recent Developments and Future Outlook

6. KEY THERAPEUTIC AREAS
6.1. Chapter Overview
6.2. Hematological Malignancies
6.2.1. Leukemias and Lymphomas
6.2.1.1. Leukemia: Introduction and Epidemiology
6.2.1.1.1. Acute Myeloid Leukemia
6.2.1.1.2. Chronic Myeloid Leukemia
6.2.1.1.3. Acute Lymphocytic Leukemia
6.2.1.1.4. Chronic Lymphocytic Leukemia

6.2.1.2. Lymphoma: Introduction and Epidemiology
6.2.1.3. Current Treatment Landscape
6.2.1.3.1. Targeted Therapies
6.2.1.3.2. ADC Therapeutics for Leukemia / Lymphoma

6.2.2. Multiple Myeloma
6.2.2.1. Introduction and Epidemiology
6.2.2.2. Current Treatment Landscape
6.2.2.3. ADC Therapeutics for Multiple Myeloma

6.3. Solid Tumors
6.3.1. Lung Cancer
6.3.1.1. Introduction and Epidemiology
6.3.1.2. Current Treatment Landscape
6.3.1.3. ADC Therapeutics for Lung Cancer

6.3.2. Breast Cancer
6.3.2.1. Introduction and Epidemiology
6.3.2.2. Current Treatment Landscape
6.3.2.3. ADC Therapeutics for Breast Cancer

6.3.3. Ovarian Cancer
6.3.3.1. Introduction and Epidemiology
6.3.3.2. Current Treatment Landscape
6.3.3.3. ADC Therapeutics for Ovarian Cancer

6.3.4. Bladder Cancer
6.3.4.1. Introduction and Epidemiology
6.3.4.2. Current Treatment Landscape
6.3.4.3. ADC Therapeutics for Bladder Cancer

6.3.5. Colorectal Cancer
6.3.5.1. Introduction and Epidemiology
6.3.5.2. Current Treatment Landscape
6.3.5.3. ADC Therapeutics for Colorectal Cancer

6.3.6. Prostate Cancer
6.3.6.1. Introduction and Epidemiology
6.3.6.2. Current Treatment Landscape
6.3.6.3. ADC Therapeutics for Prostate Cancer

6.3.7. Gastric Cancer
6.3.7.1. Introduction and Epidemiology
6.3.7.2. Current Treatment Landscape
6.3.7.3. ADC Therapeutics for Gastric Cancer

7. KEY OPINION LEADERS
7.1. Chapter Overview
7.2. Methodology

7.3. Principal Investigators Involved in Clinical Trials
7.3.1. Geographical Distribution of Key Opinion Leaders
7.3.1.1. Experts on Adcetris
7.3.1.2. Experts on Kadcyla
7.3.1.3. Experts on Mylotarg
7.3.1.4. Experts on Other ADCs

7.4. Prominent Key Opinion Leaders (KOLs)
7.5. KOL Benchmarking: Roots Analysis versus Third Party Scoring

7.6. Most Active Key Opinion Leaders
7.6.1. KOL Profile: KOL A (Celgene)
7.6.2. KOL Profile: KOL B (Georgetown University and Medical centre)
7.6.3. KOL Profile: KOL C (Cancer Hospital and Institute)
7.6.4. KOL Profile: KOL D (Comprehensive Cancer Centers of Nevada)

8. TARGET COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Key Parameters
8.3. Methodology
8.4. Competitiveness Analysis: Key Clinical Targets for ADCs
8.4.1. Four-Dimensional Bubble Analysis
8.4.2. Five-Dimensional Spider Web Analysis

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Antibody Drug Conjugates: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Most Active Players: Analysis by Number of Partnerships
9.3.4. Regional Analysis
9.3.4.1. Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. Antibody Drug Conjugates: Funding and Investment Analysis
10.3.1. Analysis by Year of Investment
10.3.2. Analysis by Number of Funding Instances
10.3.3. Analysis by Amount Invested
10.3.4. High Value Deals: Analysis by Year of Investment
10.3.5. Analysis by Type of Funding

10.3.6. Most Active Players
10.3.6.1. Analysis by Number of Funding Instances
10.3.6.2. Analysis by Amount Invested

10.3.7. Most Active Investors: Analysis by Number of Instances
10.4. Concluding Remarks

11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Antibody Drug Conjugates: Patent Analysis
11.3.1. Analysis by Publication Year
11.3.2. Analysis by Geography
11.3.3. Analysis by CPC Symbols
11.3.4. Emerging Focus Areas
11.3.5. Analysis by Type of Organization
11.3.6. Leading Players: Analysis by Number of Patents
11.4. Antibody Drug Conjugates: Benchmarking Patent Analysis
11.4.1. Analysis by Patent Characteristics
11.5. Antibody Drug Conjugates: Patent Valuation Analysis

12. ACADEMIC GRANTS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Antibody Drug Conjugates: List of Academic Grants
12.3.1. Analysis by Year of Grant Award
12.3.2. Analysis by Grant Amount Awarded
12.3.3. Analysis by Administering Institute Center
12.3.4. Analysis by Support Period
12.3.5. Analysis by Funding Institute Center and Support Period
12.3.6. Analysis by Type of Grant Application
12.3.7. Analysis by Purpose of Grant Award
12.3.8. Analysis by Activity Code
12.3.9. Emerging Focus Areas
12.3.10. Analysis by Study Section Involved
12.3.11. Popular NIH Departments: Analysis by Number of Grants
12.3.12. Analysis by Type of Recipient Organization
12.3.13. Prominent Program Officers: Analysis by Number of Grants
12.3.14. Popular Recipient Organizations: Analysis by Number of Grants
12.3.15. Regional Distribution of Recipient Organizations

13. CLINICAL TRIAL ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Antibody Drug Conjugates: Clinical Trial Analysis
13.3.1. Analysis by Trial Registration Year
13.3.2. Analysis by Trial Phase
13.3.3. Analysis by Trial Recruitment Status
13.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
13.3.5. Analysis by Study Design
13.3.6. Analysis by Sponsor / Collaborator
13.3.7. Most Active Players: Analysis by Number of Registered Trials
13.3.8. Emerging Focus Areas
13.3.9. Analysis by Trial Phase and Target Disease Indication
13.3.10. Geographical Analysis by Number of Clinical Trials
13.3.11. Geographical Analysis by Number of Patients Enrolled

14. KEY COMMMERCIALIZATION STRATEGIES
14.1. Chapter Overview
14.2. Successful Drug Launch Strategy: ROOTS Framework
14.3. Successful Drug Launch Strategy: Product Differentiation
14.4. Common Commercialization Strategies Adopted Based on Development Stage of Product

14.5. Approved ADCs: An Overview
14.5.1. Adcetris
14.5.2. Kadcyla
14.5.3. Mylotarg
14.5.4. Besponsa
14.5.5. Lumoxity
14.5.6. Polivy

14.6. Key Commercialization Strategies Adopted by the Companies Developing Antibody Drug Conjugates
14.6.1. Strategies Adopted Before the Approval of Drug
14.6.1.1. Participation in Global Events
14.6.1.1.1. Adcetris
14.6.1.1.2. Kadcyla
14.6.1.1.3. Mylotarg
14.6.1.1.4. Besponsa
14.6.1.1.5. Lumoxiti
14.6.1.1.6. Polivy
14.6.1.2. Collaboration with External Stakeholders and Pharmaceutical Firms
14.6.1.2.1. Adcetris
14.6.1.2.2. Kadcyla
14.6.2. Strategies Adopted During / Post Approval of Drug
14.6.2.1. Geographical Expansion
14.6.2.1.1. Adcetris
14.6.2.1.2. Kadcyla
14.6.2.1.3. Besponsa

14.6.2.2. Participation in Global Events Post Product Approval
14.6.2.2.1. Adcetris
14.6.2.2.2. Kadcyla
14.6.2.2.3. Mylotarg
14.6.2.2.4. Besponsa
14.6.2.2.5. Lumoxiti

14.6.2.3. Awareness Through Product Websites
14.6.2.4. Collaboration with External Stakeholders and Pharmaceutical Firms
14.6.2.4.1. Adcetris
14.6.2.4.2. Lumoxiti
14.7. Concluding Remarks

15. PROMOTIONAL ANALYSIS
15.1. Chapter Overview
15.2. Channels Used for Promotional Campaigns
15.3. Summary of Product Website Analysis
15.4. Summary of Patient Brochure and Informative Downloads

15.5. Adcetris: Promotional Analysis
15.5.1. Product Website Analysis
15.5.1.1. Messages for Healthcare Professionals
15.5.1.2. Messages for Patients
15.5.2. Patient Support Services and Informative Downloads
15.5.3. Other Promotional Activities
15.5.3.1. Participation in Conferences

15.6. Kadcyla: Promotional Analysis
15.6.1. Product Website Analysis
15.6.1.1. Messages for Healthcare Professionals
15.6.1.2. Messages for Patients
15.6.2. Patient Support Services and Informative Downloads
15.6.3. Other Promotional Activities
15.6.3.1. Participation in Conferences

15.7. Mylotarg: Promotional Analysis
15.7.1. Product Website Analysis
15.7.1.1. Messages for Healthcare Professionals
15.7.1.2. Messages for Patients
15.7.2. Patient Support Services and Informative Downloads
15.7.3. Other Promotional Activities
15.7.3.1. Participation in Conferences

15.8. Besponsa: Promotional Analysis
15.8.1. Product Website Analysis
15.8.1.1. Messages for Healthcare Professionals
15.8.1.2. Messages for Patients
15.8.2. Patient Support Services and Informative Downloads
15.8.3. Other Promotional Activities
15.8.3.1. Participation in Conferences

15.9. Lumoxiti: Promotional Analysis
15.9.1. Product Website Analysis
15.9.1.1. Messages for Healthcare Professionals
15.9.1.2. Messages for Patients
15.9.2. Patient Support Services and Informative Downloads
15.9.3. Other Promotional Activities
15.9.3.1. Participation in Conferences

15.10. Polivy: Promotional Analysis
15.10.1. Product Website Analysis
15.10.1.1. Messages for Healthcare Professionals
15.10.1.2. Messages for Patients
15.10.2. Patient Support Services and Informative Downloads
15.10.3. Other Promotional Activities
15.10.3.1. Participation in Conferences

16. COMBINATION THERAPIES
16.1. Chapter Overview
16.2. Combination Therapy: History of Development

16.3. Combination Therapy: FDA Guidelines
16.3.1. Combinations of Marketed Drugs
16.3.2. Combinations of Marketed Drugs with New Molecular Entities
16.3.3. Combinations of New Molecular Entities 

16.4. Combination Therapies: ADCs
16.4.1. Completed / Ongoing Clinical Studies of ADCs
16.4.1.1. Analysis by Type of Therapy
16.4.2. Completed / Ongoing Clinical Studies of ADC-Based Combination Therapies 
16.4.2.1. Analysis by Highest Phase of Development
16.4.2.2. Analysis by Current Trial Status
16.4.2.3. Analysis by Type of Combination Therapy
16.4.2.4. Analysis by Target Disease Indication and Type of Combination Therapy

17. NOVEL CONJUGATION TECHNOLOGY PLATFORMS
17.1. Chapter Overview
17.2. First Generation ADC Technologies

17.3. Second Generation ADC Technologies
17.3.1. Cysteine and Selenocysteine Engineering
17.3.2. Unnatural Amino Acid Engineering
17.3.3. Amino-Terminal Serine Engineering

17.4. Third Generation ADC Technologies
17.4.1. Enzyme-Assisted Ligation Approaches
17.4.2. Glycan Remodeling Approaches
17.4.3. Ligation at Fab Nucleotide-Binding Site
17.4.4. Cysteine Rebridging
17.4.5. Avoiding or Limiting Retro-Michael Drug Deconjugation
17.5. Other Emerging ADC Technologies
17.6. Evolutionary Analysis

18. ASSESMENT OF NON-CLINICAL DATA, FIRST IN HUMAN DOSING
18.1. Chapter Overview
18.2. ADCs and Non-Clinical Studies
18.3. ICH S9 Guidelines
18.4. Investigational New Drug (IND)-Enabling Study Designs
18.4.1. Example Case: Kadcyla

18.5. Toxicities in Animal Models
18.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans
18.7. Other Key Considerations for Study Design

19. COST PRICE ANALYSIS
19.1. Chapter Overview
19.2. Factors Contributing Towards the High Price of Antibody Drug Conjugates
19.3. Antibody Drug Conjugates Market: Pricing Models
19.3.1. On the Basis of Associated Costs
19.3.2. On the Basis of Competition
19.3.3. On the Basis of Patient Segment
19.4. Reimbursement Considerations for Antibody Drug Conjugates

20. CASE STUDY: CONTRACT MANUFACTURING OF ADCs 
20.1. Chapter Overview
20.2. Key Steps for ADC Manufacturing
20.3. Technical Challenges Associated with ADC Manufacturing
20.4. Challenges Associated with Supply Chain and Method Transfer
20.5. Limitations of In-House Manufacturing
20.6. Investments in ADC Manufacturing Capability Expansions
20.7. Collaborations Established for ADC Manufacturing
20.8. Growing Demand for ADC Contract Manufacturing
20.9. Emergence of Start-Ups Offering Contract Services
20.10. CMOs with Linker Manufacturing Capabilities
20.11. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities
20.12. CMOs with Conjugation Capabilities
20.13. ADC One-stop-shops

21. CASE STUDY: COMPANION DIAGNOSTICS FOR ADC THERAPEUTICS
21.1. Chapter Overview
21.1.1. Advantages of Companion Diagnostics
21.1.2. Challenges Associated with the Development of Companion Diagnostics

21.2. Companion Diagnostics for ADC Therapeutics
21.3. Other Companion Diagnostics
21.3.1. Analysis by Type of Target Antigen
21.3.2. Analysis by Type of Cancer
21.4. Most Active Players: Analysis by Number of Companion Diagnostics Developed

22. SWOT ANALYSIS
22.1. Chapter Overview
22.2. Strengths
22.3. Weaknesses
22.4. Opportunities
22.5. Threats

23. MARKET FORECAST AND OPPORTUNITY ANALYSIS
23.1. Chapter Overview
23.2. Scope and Limitations
23.3. Forecast Methodology

23.4. Overall Antibody Drug Conjugates Market
23.4.1. Antibody Drug Conjugates Market: Distribution by Target Disease Indication
23.4.2. Antibody Drug Conjugates Market: Distribution by Type of Linker
23.4.3. Antibody Drug Conjugates Market: Distribution by Type of Payload
23.4.4. Antibody Drug Conjugates Market: Distribution by Target Antigen
23.4.5. Antibody Drug Conjugates Market: Distribution by Geography

23.5. Antibody Drug Conjugates Market: Individual Drug Sales Forecasts
23.5.1. Adcetris
23.5.1.1. Target Patient Population
23.5.1.2. Sales Forecast

23.5.2. Kadcyla
23.5.2.1. Target Patient Population
23.5.2.2. Sales Forecast

23.5.3. Mylotarg
23.5.3.1. Target Patient Population
23.5.3.2. Sales Forecast

23.5.4. Besponsa
23.5.4.1. Target Patient Population
23.5.4.2. Sales Forecast

23.5.5. Lumoxiti
23.5.5.1. Target Patient Population
23.5.5.2. Sales Forecast

23.5.6. Polivy
23.5.6.1. Target Patient Population
23.5.6.2. Sales Forecast

23.5.7. Trodelvy
23.5.7.1. Target Patient Population
23.5.7.2. Sales Forecast

23.5.8. Enhertu
23.5.8.1. Target Patient Population
23.5.8.2. Sales Forecast

23.5.9. Zynlonta
23.5.9.1. Target Patient Population
23.5.9.2. Sales Forecast

23.5.10. Blenrep
23.5.10.1. Target Patient Population
23.5.10.2. Sales Forecast

23.5.11. Padcev
23.5.11.1. Target Patient Population
23.5.11.2. Sales Forecast

23.5.12. Tisotumab vedotin
23.5.12.1. Target Patient Population
23.5.12.2. Sales Forecast

23.5.13. Mirvetuximab soravtansine
23.5.13.1. Target Patient Population
23.5.13.2. Sales Forecast

23.5.14. ABBV-3373
23.5.14.1. Target Patient Population
23.5.14.2. Sales Forecast

23.5.15. Anetumab ravtansine
23.5.15.1. Target Patient Population
23.5.15.2. Sales Forecast

23.5.16. Disitamab vedotin
23.5.16.1. Target Patient Population
23.5.16.2. Sales Forecast

23.5.17. MRG002
23.5.17.1. Target Patient Population
23.5.17.2. Sales Forecast

23.5.18. Naratuximab emtansine
23.5.18.1. Target Patient Population
23.5.18.2. Sales Forecast

23.5.19. Trastuzumab duocarmazine
23.5.19.1. Target Patient Population
23.5.19.2. Sales Forecast

23.5.20. Tusamitamab ravtansine
23.5.20.1. Target Patient Population
23.5.20.2. Sales Forecast

23.5.21. Cetuximab sarotalocan
23.5.21.1. Target Patient Population
23.5.21.2. Sales Forecast

23.5.22. BA3011
23.5.22.1. Target Patient Population
23.5.22.2. Sales Forecast

24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Oxford Biotherapeutics
24.2.1. Company Snapshot
24.2.2. Interview Transcript: Christian Rohlff, Founder and Chief Executive Officer

24.3. Angiex
24.3.1. Company Snapshot
24.3.2. Interview Transcript: Paul Jaminet, Founder and Chief Executive Officer

24.4. Syndivia
24.4.1. Company Snapshot
24.4.2. Interview Transcript: Sasha Koniev, Co-Founder and Chief Executive Officer

24.5. BSP Pharmaceuticals
24.5.1. Company Snapshot
24.5.2. Interview Transcript: Aldo Braca, President and Chief Executive Officer and Giorgio Salciarini, Technical Business Development Senior Manager

24.6. Abzena
24.6.1. Company Snapshot
24.6.2. Interview Transcript: John Burt, Chief Executive Officer

24.7. CureMeta
24.7.1. Company Snapshot
24.7.2. Interview Transcript: Michael Schopperle, Chief Executive Officer

24.8. CytomX
24.8.1. Company Snapshot
24.8.2. Interview Transcript: Jeff Landau, Chief Business Officer and Head of Strategy

24.9. NBE-Therapeutics
24.9.1. Company Snapshot
24.9.2. Interview Transcript: Wouter Verhoeven, Chief Business Officer

24.10. Cerbios-Pharma
24.10.1. Company Snapshot
24.10.2. Interview Transcript: Denis Angioletti, Chief Commercial Officer

24.11. Eisai
24.11.1. Company Snapshot
24.11.2. Interview Transcript: Toshimitsu Uenaka, Executive Director and Takashi Owa, Chief Innovation Officer

24.12. AbTis
24.12.1. Company Snapshot
24.12.2. Interview Transcript: Justin Oh, Executive Director

24.13. AmbrX
24.13.1. Company Snapshot
24.13.2. Interview Transcript: Sukumar Sakamuri, Vice President and Head of Chemistry

24.14. Synaffix
24.14.1. Company Snapshot
24.14.2. Interview Transcript: Anthony DeBoer, Director, Business Development

24.15. Pierre Fabre
24.15.1. Company Snapshot
24.15.2. Interview Transcript: Christian Bailly, Director of CDMO

24.16. Catalent Pharma Solutions
24.16.1. Company Snapshot
24.16.2. Interview Transcript: Jennifer L. Mitcham, Director, SMARTag ADCs and Bioconjugates and Stacy McDonald, Group Product Manager

24.17. Lonza
24.17.1. Company Snapshot
24.17.2. Interview Transcript: Laurent Ducry, Head of Bioconjugates Commercial Development

24.18. Piramal Healthcare
24.18.1. Company Snapshot
24.18.2. Interview Transcript: Mark Wright, Site Head

24.19. Ajinomoto Bio-Pharma Services
24.19.1. Company Snapshot
24.19.2. Interview Transcript: Tatsuya Okuzumi, Associate General Manager

24.20. Cardiff University
24.20.1. Company Snapshot
24.20.2. Interview Transcript: Alan Burnett, Professor, School of Medicine

24.21. Anonymous, Chief Executive Officer, a Leading CMO
24.22. Anonymous, Director, Business Development, Leading CMO

25. CONCLUSION

26. APPENDIX 1: TABULATED DATA

27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Historical Timeline of Cancer Therapies
Figure 3.2 Cancer Treatment: Type of Surgeries
Figure 3.3 Cancer Treatment: Type of Radiation Therapies
Figure 3.4 Cancer Treatment: Type of Chemotherapies
Figure 3.5 Components of an ADC
Figure 3.6 Comparative Study of Pharmacokinetic Properties of ADCs: Dosing Regimen, Cmax and T1/2
Figure 4.1 Antibody Drug Conjugates: Distribution by Phase of Development
Figure 4.2 Antibody Drug Conjugates: Distribution by Target Disease Indication
Figure 4.3 Antibody Drug Conjugates: Key Solid Tumor Indications
Figure 4.4 Antibody Drug Conjugates: Key Hematological Malignancies
Figure 4.5 Antibody Drug Conjugates: Distribution by Line of Treatment
Figure 4.6 Antibody Drug Conjugates: Distribution by Dosing Regimen
Figure 4.7 Antibody Drug Conjugates: Distribution by Type of Therapy
Figure 4.8 Antibody Drug Conjugates: Distribution by Target Antigen
Figure 4.9 Antibody Drug Conjugates: Distribution by Antibody Origin
Figure 4.10 Antibody Drug Conjugates: Distribution by Antibody Isotype
Figure 4.11 Antibody Drug Conjugates: Distribution by Type of Linker
Figure 4.12 Antibody Drug Conjugates: Distribution by Type of Payload / Warhead
Figure 4.13 Antibody Drug Conjugates: Distribution by Target Antigens and Target Disease Indications
Figure 4.14 Antibody Drug Conjugates: Grid Analysis
Figure 4.15 Antibody Drug Conjugate Developers: Distribution by Year of Establishment
Figure 4.16 Antibody Drug Conjugate Developers: Distribution by Company Size
Figure 4.17 Antibody Drug Conjugate Developers: Distribution by Location of Headquarters
Figure 4.18 Most Active Players: Distribution by Number of Therapies
Figure 4.19 Logo Landscape: Distribution by Target Disease Indication and Company Size
Figure 5.1 Seagen: Annual Revenues, 2016 – Q1 2021 (USD Million)
Figure 5.2 Roche / Genentech: Annual Revenues, 2016 – 2020 (CHF Million)
Figure 5.3 Pfizer: Annual Revenues, 2016 – Q1 2021 (USD Billion)
Figure 5.4 AstraZeneca: Annual Revenues, 2016 – Q1 2021 (USD Million)
Figure 5.5 Astellas Pharma: Annual Revenues, 2016 – 2020 (JPY Million)
Figure 5.6 ImmunoGen: Annual Revenues, 2016 – Q1 2021 (USD Million)
Figure 5.7 Daiichi Sankyo: Annual Revenues, 2016 – 2020 (JPY Million)
Figure 5.8 Gilead: Annual Revenues, 2016 – 2020 (USD Million)
Figure 5.9 AbbVie: Annual Revenues, 2016 – 2020 (USD Billion)
Figure 5.10 Bayer: Annual Revenues, 2016 – 2020 (EUR Million)
Figure 6.1 Leukemia: Disease Classification
Figure 6.2 Leukemia: Global Epidemiological Distribution
Figure 6.3 Lymphoma: Global Epidemiological Distribution
Figure 6.4 Multiple Myeloma: Global Epidemiological Distribution
Figure 6.5 Lung Cancer: Disease Classification
Figure 6.6 Lung Cancer: Global Epidemiological Distribution
Figure 6.7 Breast Cancer: Global Epidemiological Distribution
Figure 6.8 Ovarian Cancer: Global Epidemiological Distribution
Figure 6.9 Bladder Cancer: Global Epidemiological Distribution
Figure 6.10 Colorectal Cancer: Global Epidemiological Distribution
Figure 6.11 Prostate Cancer: Global Epidemiological Distribution
Figure 6.12 Gastric Cancer: Global Epidemiological Distribution
Figure 7.1 Adcetris: Geographical Distribution of Principle Investigators
Figure 7.2 Kadcyla: Geographical Distribution of Principle Investigators
Figure 7.3 Mylotarg: Geographical Distribution of Principle Investigators
Figure 7.4 Other ADCs: Geographical Distribution of Principle Investigators
Figure 7.5 KOL Analysis: Dot-Plot of Principal Investigators
Figure 7.6 KOL Benchmarking: Roots Analysis versus Third Party Scoring
Figure 7.7 KOL Analysis: Most Prominent KOLs
Figure 8.1 Antibody Drug Conjugates: Four-Dimensional Bubble Analysis
Figure 8.2 Antibody Drug Conjugates: Five-Dimensional Spider-Web Analysis
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2014-2021
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Cumulative Trend by Year and Type of Partnership, 2014-2021
Figure 9.4 Most Active Players: Distribution by Number of Partnerships
Figure 9.5 Partnerships and Collaborations: Regional Distribution
Figure 9.6 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Funding and Investment Analysis: Cumulative Number of Funding Instances by Year, 2014-2021
Figure 10.2 Funding and Investment Analysis: Cumulative Amount Invested by Year, 2014-2021 (USD Million)
Figure 10.3 Funding and Investment Analysis: High Value Deals, 2014-2021 (USD Million)
Figure 10.4 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2014-2021
Figure 10.5 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2014-2021 (USD Million)
Figure 10.6 Most Active Players: Distribution by Number of Funding Instances
Figure 10.7 Most Active Players: Distribution by Amount Invested
Figure 10.8 Most Active Investors: Distribution by Number of Funding Instances
Figure 10.9 Funding and Investment Summary, 2014-2021 (USD Million)
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Distribution by Publication Year, 2001-2021
Figure 11.3 Patent Analysis: Distribution by Geography
Figure 11.4 Patent Analysis: Distribution by CPC Symbols
Figure 11.5 Patent Analysis: Emerging Focus Areas
Figure 11.6 Patent Analysis: Distribution by Type of Organization
Figure 11.7 Leading Industry Players: Distribution by Number of Patents
Figure 11.8 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.9 Patent Analysis: Benchmarking by Patent Characteristics
Figure 11.10 Patent Analysis: Benchmarking by Number of International Patents
Figure 11.11 Patent Analysis: Distribution by Patents Age (2001-2021)
Figure 11.12 Patent Analysis: Distribution of Patents by Geography (2001-2021)
Figure 11.13 Patent Analysis: Valuation Analysis
Figure 12.1 Grant Analysis: Cumulative Year-Wise Trend of Grants Awarded, 2016-2021
Figure 12.2 Grant Analysis: Distribution by Amount Awarded (USD Million), 2016-2021
Figure 12.3 Grant Analysis: Distribution by Administering Institute Center
Figure 12.4 Grant Analysis: Distribution by Support Period
Figure 12.5 Grant Analysis: Distribution by Administering Institute Center and Support Period
Figure 12.6 Grant Analysis: Distribution by Type of Grant Application
Figure 12.7 Grant Analysis: Distribution by Purpose of Grant Award
Figure 12.8 Grant Analysis: Distribution by Activity Code
Figure 12.9 Word Cloud: Emerging Focus Areas
Figure 12.10 Grant Analysis: Distribution by Study Section Involved
Figure 12.11 Popular NIH Departments: Distribution by Number of Grants
Figure 12.12 Grant Analysis: Distribution by Type of Recipient Organization
Figure 12.13 Most Prominent Program Officers: Distribution by Number of Grants
Figure 12.14 Popular Recipient Organizations: Distribution by Number of Grants
Figure 12.15 Regional Distribution of Recipient Organizations
Figure 13.1 Clinical Trial Analysis: Scope and Methodology
Figure 13.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 13.3 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, 2016-2021
Figure 13.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 13.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status, 2016-2021
Figure 13.6 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2016-2021
Figure 13.7 Clinical Trial Analysis: Distribution by Study Design
Figure 13.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 13.9 Most Active Players: Distribution by Number of Registered Trials
Figure 13.10 Clinical Trial Analysis: Emerging Focus Areas
Figure 13.11 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 13.12 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 14.1 Successful Drug Launch Strategy: ROOTS Framework
Figure 14.2 Successful Drug Launch Strategy: Product Differentiation
Figure 14.3 Common Commercialization Strategies Adopted Based on Development Stage of Product
Figure 14.4 Harvey Ball Analysis: Key Commercialization Strategies Adopted by Companies Developing ADCs
Figure 14.5 Approval of Drugs in Multiple Geographies: Historical Timeline
Figure 14.6 Approved ADC Therapeutics: Snapshot of Promotional Activities on Product Websites
Figure 15.1 Promotional / Marketing Strategy: Product Website Analysis
Figure 15.2 Promotional / Marketing Strategy: Patient Brochure and Unique Features
Figure 15.3 Promotional / Marketing Strategy: Informative Downloads
Figure 15.4 Adcetris Website Analysis: Messages for Healthcare Professionals
Figure 15.5 Adcetris Website Analysis: Messages for Patients
Figure 15.6 Adcetris Website Analysis: Patient Support Services
Figure 15.7 Kadcyla Website Analysis: Messages for Healthcare Professionals
Figure 15.8 Kadcyla Website Analysis: Messages for Patients
Figure 15.9 Kadcyla Website Analysis: Patient Support Services
Figure 15.10 Mylotarg Website Analysis: Messages for Healthcare Professionals
Figure 15.11 Mylotarg Website Analysis: Messages for Patients
Figure 15.12 Mylotarg Website Analysis: Patient Support Services
Figure 15.13 Mylotarg Website Analysis: Pfizer Oncology Together Program
Figure 15.14 Besponsa Website Analysis: Messages for Healthcare Professionals
Figure 15.15 Besponsa Website Analysis: Messages for Patients
Figure 15.16 Besponsa Website Analysis: Patient Support Services
Figure 15.17 Besponsa Website Analysis: Pfizer Oncology Together Program
Figure 15.18 Lumoxiti Website Analysis: Messages for Healthcare Professionals
Figure 15.19 Lumoxiti Website Analysis: Messages for Patients
Figure 15.20 Lumoxiti Website Analysis: Patient Support Services
Figure 15.21 Polivy Website Analysis: Messages for Healthcare Professionals
Figure 15.22 Polivy Website Analysis: Messages for Patients
Figure 15.23 Polivy Website Analysis: Patient Support Services
Figure 16.1 Antibody Drug Conjugates: Distribution by Type of Therapy Evaluation
Figure 16.2 Antibody Drug Conjugates Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
Figure 16.3 Antibody Drug Conjugates Combination Therapy Clinical Studies: Distribution by Current Trial Status
Figure 16.4 Antibody Drug Conjugates Combination Therapy Clinical Studies: Distribution by Trial Date and Type of Combination Therapy
Figure 16.5 Antibody Drug Conjugates Combination Therapy Clinical Studies: Distribution by Target Disease Indication and Type of Combination Therapy
Figure 17.1 ADC Platforms: Technological Evolution
Figure 17.2 ADC Conjugation Platforms: Technology Landscape
Figure 18.1 First in Human Dose Calculation: Dose Escalation using BSA Conversion
Figure 18.2 Relationship between Dose-Limiting Toxicities and ADC Warhead
Figure 18.3 Maximum Tolerated Dose (MTD): Relationship between Drug to Antibody Ratio and Highest Non-Severely Toxic Dose (HNSTD)
Figure 19.1 Antibody Drug Conjugates: Relative Share of Individual Processes in the Cost of Production
Figure 19.2 Antibody Drug Conjugates: Distribution by Cost of Raw Material Required for the Manufacturing of ADC at Clinical Stage (Without Licensing Fee)
Figure 19.3 Antibody Drug Conjugates: Distribution by Cost of Raw Material Required for the Manufacturing of ADC at Clinical Stage (With Licensing Fee)
Figure 19.4 Antibody Drug Conjugates: Pricing Model Based on Patient Segment
Figure 19.5 Antibody Drug Conjugates: Pricing Model Based on Reimbursement Approvals
Figure 20.1 ADC Contract Manufacturers: Distribution by Services Offered
Figure 21.1 Advantages of Companion Diagnostics
Figure 21.2 Companion Diagnostics Applicable to Antibody Drug Conjugates: Distribution by Target Antigen
Figure 21.3 Companion Diagnostics Applicable to Antibody Drug Conjugates: Distribution by Type of Cancer
Figure 21.4 Companion Diagnostics Applicable to Antibody Drug Conjugates: Key Players
Figure 22.1 Antibody Drug Conjugates: SWOT Analysis
Figure 22.2 Antibody Drug Conjugates SWOT Analysis: Strengths
Figure 22.3 Antibody Drug Conjugates SWOT Analysis: Weaknesses
Figure 22.4 Antibody Drug Conjugates SWOT Analysis: Opportunities
Figure 22.5 Antibody Drug Conjugates SWOT Analysis: Threats
Figure 23.1 Overall Antibody Drug Conjugates Market, 2021-2030 (USD Billion)
Figure 23.2 Antibody Drug Conjugates Market: Distribution by Target Disease Indication, 2021, 2025 and 2030 (USD Billion)
Figure 23.3 Antibody Drug Conjugates Market: Distribution by Type of Linker, 2021, 2025 and 2030 (USD Billion)
Figure 23.4 Antibody Drug Conjugates Market: Distribution by Type of Payload, 2021, 2025 and 2030 (USD Billion)
Figure 23.5 Antibody Drug Conjugates Market: Distribution by Type of Target Antigen, 2021, 2025 and 2030 (USD Billion)
Figure 23.6 ADC Therapeutics Market: Distribution by Geography, 2021, 2025 and 2030 (USD Billion)
Figure 23.7 Adcetris: Target Patient Population
Figure 23.8 Adcetris Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.9 Kadcyla: Target Patient Population
Figure 23.10 Kadcyla Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.11 Mylotarg: Target Patient Population
Figure 23.12 Mylotarg Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.13 Besponsa: Target Patient Population
Figure 23.14 Besponsa Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.15 Lumoxiti: Target Patient Population
Figure 23.16 Lumoxiti Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.17 Polivy: Target Patient Population
Figure 23.18 Polivy Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.19 Trodelvy: Target Patient Population
Figure 23.20 Trodelvy Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.21 Enhertu: Target Patient Population
Figure 23.22 Enhertu Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.23 Zynlonta: Target Patient Population
Figure 23.24 Zynlonta Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.25 Blenrep: Target Patient Population
Figure 23.26 Blenrep Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.27 Padcev: Target Patient Population
Figure 23.28 Padcev Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.29 Tisotumab Vedotin: Target Patient Population
Figure 23.30 Tisotumab Vedotin Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.31 Mirvetuximab Soravtansine: Target Patient Population
Figure 23.32 Mirvetuximab Soravtansine Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.33 ABBV-3373: Target Patient Population
Figure 23.34 ABBV-3373 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.35 Anetumab Ravtansine: Target Patient Population
Figure 23.36 Anetumab Ravtansine Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.37 Disitamab Vedotin: Target Patient Population
Figure 23.38 Disitamab Vedotin Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.39 MRG002: Target Patient Population
Figure 23.40 MRG002 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.41 Naratuximab Emtansine: Target Patient Population
Figure 23.42 Naratuximab Emtansine Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.43 Trastuzumab Duocarmazine: Target Patient Population
Figure 23.44 Trastuzumab Duocarmazine Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.45 Tusamitamab Ravtansine: Target Patient Population
Figure 23.46 Tusamitamab Ravtansine Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.47 Cetuximab Sarotalocan: Target Patient Population
Figure 23.48 Cetuximab Sarotalocan Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.49 BA3011: Target Patient Population
Figure 23.50 BA3011 Sales Forecast (Till 2030): Base Scenario (USD Million)

List Of Tables

Table 3.1 List of Approved Monoclonal Antibody Therapies
Table 3.2 Commonly Used Cytotoxins for Antibody Drug Conjugates
Table 3.3 Occupational Exposure Limit Bands, SafeBridge Consultants
Table 3.4 Comparison of Pharmacokinetic Properties: ADCs, Small Molecules and Monoclonal Antibodies
Table 4.1 Antibody Drug Conjugates: Drug Pipeline
Table 4.2 Antibody Drug Conjugates: Component Specific Details
Table 4.3 Antibody Drug Conjugates: Distribution by Target Antigen and Target Disease Indication(s)
Table 4.4 Antibody Drug Conjugates: List of Developers
Table 4.5 Antibody Drug Conjugates: Technology Platforms
Table 4.6 Novel Drug Conjugates
Table 4.7 Antibody Drug Conjugates: Discontinued Drugs
Table 5.1 Seagen: Company Overview
Table 5.2 Seagen: Antibody Drug Conjugates Pipeline
Table 5.3 Drug Profile: Adcetris
Table 5.4 Drug Profile: Padcev
Table 5.5 Drug Profile: HuMax-TF
Table 5.6 Drug Profile: SGN-LIV1A
Table 5.7 Seagen: Recent Developments and Future Outlook
Table 5.8 Roche / Genentech: Company Overview
Table 5.9 Roche / Genentech: Antibody Drug Conjugates Pipeline
Table 5.10 Drug Profile: Kadcyla
Table 5.11 Drug Profile: Polivy
Table 5.12 Roche / Genentech: Recent Developments and Future Outlook
Table 5.13 Pfizer: Company Overview
Table 5.14 Pfizer: Antibody Drug Conjugates Pipeline
Table 5.15 Drug Profile: Mylotarg
Table 5.16 Drug Profile: Besponsa
Table 5.17 Pfizer: Recent Developments and Future Outlook
Table 5.18 AstraZeneca: Company Overview
Table 5.19 AstraZeneca: Antibody Drug Conjugates Pipeline
Table 5.20 Drug Profile: Enhertu
Table 5.21 AstraZeneca: Recent Developments and Future Outlook
Table 5.22 Astellas Pharma: Company Overview
Table 5.23 Astellas Pharma: Antibody Drug Conjugates Pipeline
Table 5.24 Astellas Pharma: Recent Developments and Future Outlook
Table 5.25 ImmunoGen: Company Overview
Table 5.26 ImmunoGen: Antibody Drug Conjugates Pipeline
Table 5.27 Drug Profile: Mirvetuximab soravtansine
Table 5.28 ImmunoGen: Recent Developments and Future Outlook
Table 5.29 Daiichi Sankyo: Company Overview
Table 5.30 Daiichi Sankyo: Antibody Drug Conjugates Pipeline
Table 5.31 Drug Profile: Patritumab deruxtecan
Table 5.32 Drug Profile: Datopotamab deruxtecan
Table 5.33 Daiichi Sankyo: Recent Developments and Future Outlook
Table 5.34 Gilead: Company Overview
Table 5.35 Gilead: Antibody Drug Conjugates Pipeline
Table 5.36 Drug Profile: Trodelvy
Table 5.37 Gilead: Recent Developments and Future Outlook
Table 5.38 AbbVie: Company Overview
Table 5.39 AbbVie: Antibody Drug Conjugates Pipeline
Table 5.40 Drug Profile: Telisotuzumab vedotin
Table 5.41 Drug Profile: ABBV-3373
Table 5.42 AbbVie: Recent Developments and Future Outlook
Table 5.43 Bayer: Company Overview
Table 5.44 Bayer: Antibody Drug Conjugates Pipeline
Table 5.45 Drug Profile: Anetumab ravtansine
Table 5.46 Bayer: Recent Developments and Future Outlook
Table 5.47 RemeGen: Company Overview
Table 5.48 RemeGen: Antibody Drug Conjugates Pipeline
Table 5.49 Drug Profile: Disitamab vedotin
Table 5.50 RemeGen: Recent Developments and Future Outlook
Table 5.51 ADC Therapeutics: Company Overview
Table 5.52 ADC Therapeutics: Antibody Drug Conjugates Pipeline
Table 5.53 Drug Profile: Zynlonta
Table 5.54 Drug Profile: Camidanlumab tesirine
Table 5.55 ADC Therapeutics: Recent Developments and Future Outlook
Table 6.1 Comparison between Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 6.2 Leukemia: List of Marketed Targeted Therapeutics
Table 6.3 Lymphoma: List of Marketed Targeted Therapeutics
Table 6.4 ADC Therapeutics for Leukemia and Lymphoma
Table 6.5 Multiple Myeloma: List of Marketed Targeted Therapeutics
Table 6.6 ADC Therapeutics for Multiple Myeloma
Table 6.7 Lung Cancer: List of Marketed Targeted Therapeutics
Table 6.8 ADC Therapeutics for Lung Cancer
Table 6.9 Breast Cancer: List of Marketed Targeted Therapeutics
Table 6.10 ADC Therapeutics for Breast Cancer
Table 6.11 Ovarian Cancer: List of Marketed Targeted Therapeutics
Table 6.12 ADC Therapeutics for Ovarian Cancer
Table 6.13 Bladder Cancer: List of Marketed Targeted Therapeutics
Table 6.14 ADC Therapeutics for Bladder Cancer
Table 6.15 Colorectal Cancer: List of Marketed Targeted Therapeutics
Table 6.16 ADC Therapeutics for Colorectal Cancer
Table 6.17 Prostate Cancer: List of Marketed Targeted Therapeutics
Table 6.18 ADC Therapeutics for Prostate Cancer
Table 6.19 Gastric Cancer: List of Marketed Targeted Therapeutics
Table 6.20 ADC Therapeutics for Gastric Cancer
Table 7.1 KOLs: List of Principal Investigators
Table 7.2 KOLs: List of Universities and Hospitals
Table 7.3 KOLs: Roots Analysis Proprietary Scoring System
Table 7.4 KOL Profile: KOL A (Celgene)
Table 7.5 KOL Profile: KOL B (Georgetown University Medical Center)
Table 7.6 KOL Profile: KOL C (Cancer Hospital and Institute)
Table 7.7 KOL Profile: KOL D (Comprehensive Cancer Centers of Nevada)
Table 9.1 Antibody Drug Conjugates: List of Partnerships and Collaborations, 2014-2021
Table 10.1 Antibody Drug Conjugates: List of Funding and Investments, 2014-2021
Table 10.2 Funding and Investments: Average Amount Invested by Year, 2014-2021 (USD Million)
Table 11.1 Patent Analysis: Prominent CPC Symbols
Table 11.2 Patent Analysis: List of Top CPC Symbols
Table 11.3 Patent Portfolio: Summary of Benchmarking Analysis
Table 11.4 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.5 Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 12.1 Antibody Drug Conjugates: List of Academic Grants, 2016-2021
Table 14.1 Adcetris: Drug Overview
Table 14.2 Kadcyla: Drug Overview
Table 14.3 Mylotarg: Drug Overview
Table 14.4 Besponsa: Drug Overview
Table 14.5 Lumoxiti: Drug Overview
Table 14.6 Polivy: Drug Overview
Table 14.7 Adcetris: Participation in Conferences Before Product Approval
Table 14.8 Mylotarg: Participation in Conferences Before Product Approval
Table 14.9 Kadcyla: Participation in Conferences Before Product Approval
Table 14.10 Besponsa: Participation in Conferences Before Product Approval
Table 14.11 Lumoxiti: Participation in Conferences Before Product Approval
Table 14.12 Polivy: Participation in Conferences Before Product Approval
Table 14.13 Adcetris: Participation in Conferences Post Product Approval
Table 14.14 Kadcyla: Participation in Conferences Post Product Approval
Table 14.15 Key Commercialization Strategies: Harvey Ball Analysis by Ease of Implementation, Value Addition and Current Adoption
Table 16.1 Antibody Drug Conjugates Combination Therapy Clinical Studies: Key Indications
Table 17.1 Second-Generation ADC Technologies: Cysteine and Selenocysteine Engineering
Table 17.2 Second-Generation ADC Technologies: Unnatural Amino Acid Engineering
Table 17.3 Second-Generation ADC Technologies: Amino-terminal Engineered Serine
Table 17.4 Third-Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 17.5 Third-Generation ADC Technologies: Glycan Remodeling Approaches
Table 17.6 Third-Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 17.7 Third-Generation ADC Technologies: Cysteine Rebridging
Table 17.8 Third-Generation ADC Technologies: Avoiding or Limiting Retro-Michael Drug Deconjugation
Table 18.1 ADC Therapeutics Non-Clinical Studies: Safety Packages Required
Table 18.2 Single Dose Study of Kadcyla in Cynomolgus Monkey
Table 18.3 ADC Therapeutics: Dose Limiting Toxicities in Clinical Studies
Table 19.1 ADC Components: Information on Cost by Type of Linker
Table 19.2 ADC Components: Information on Cost by Type of Cytotoxin
Table 19.3 Price of Marketed ADCs
Table 19.4 Price of Other Marketed Targeted Therapies
Table 20.1 List of Contract Manufacturers and Their Capabilities in ADC Manufacturing
Table 20.2 List of HPAPI and Cytotoxic Drugs Manufacturing Service Providers
Table 20.3 Contract Manufacturers for ADC Therapeutics: Geographical Distribution
Table 20.4 One Stop Shops for ADC Manufacturing: Information on Location of Manufacturing Facilities
Table 21.1 Companion Diagnostics: List of Available / Under Development Tests for ADCs
Table 21.2 Companion Diagnostics: List of Available / Under Development Tests for Clinical ADCs
Table 21.3 Companion Diagnostics: Partnerships and Collaborations, 2014-2019
Table 21.4 Companion Diagnostics Applicable to ADC Therapeutics: List of Available / Under Development Tests
Table 23.1 ADC Therapeutics: Information on Expected Launch Year
Table 24.1 Oxford Biotherapeutics: Company Snapshot
Table 24.2 Angiex: Company Snapshot
Table 24.3 Syndivia: Company Snapshot
Table 24.4 BSP Pharmaceuticals: Company Snapshot
Table 24.5 Abzena: Company Snapshot
Table 24.6 CureMeta: Company Snapshot
Table 24.7 CytomX: Company Snapshot
Table 24.8 NBE-Therapeutics: Company Snapshot
Table 24.9 Cerbios-Pharma: Company Snapshot
Table 24.10 Eisai: Company Snapshot
Table 24.11 AbTis: Company Snapshot
Table 24.12 AmbrX: Company Snapshot
Table 24.13 Synaffix: Company Snapshot
Table 24.14 Pierre Fabre: Company Snapshot
Table 24.15 Catalent Pharma Solutions: Company Snapshot
Table 24.16 Lonza: Company Snapshot
Table 24.17 Piramal Healthcare: Company Snapshot
Table 24.18 Ajinomoto Bio-Pharma Services: Company Snapshot
Table 24.19 Cardiff University: Company Snapshot
Table 26.1 Antibody Drug Conjugates: Distribution by Phase of Development
Table 26.2 Antibody Drug Conjugates: Distribution by Target Disease Indication
Table 26.3 Antibody Drug Conjugates: Key Solid Tumor Indications
Table 26.4 Antibody Drug Conjugates: Key Hematological Malignancies
Table 26.5 Antibody Drug Conjugates: Distribution by Line of Treatment
Table 26.6 Antibody Drug Conjugates: Distribution by Dosing Regimen
Table 26.7 Antibody Drug Conjugates: Distribution by Type of Therapy
Table 26.8 Antibody Drug Conjugates: Distribution by Target Antigen
Table 26.9 Antibody Drug Conjugates: Distribution by Antibody Origin
Table 26.10 Antibody Drug Conjugates: Distribution by Antibody Isotype
Table 26.11 Antibody Drug Conjugates: Distribution by Type of Linker
Table 26.12 Antibody Drug Conjugates: Distribution by Type of Payload / Warhead
Table 26.13 Antibody Drug Conjugates: Distribution by Target Antigens and Target Disease Indications
Table 26.14 Antibody Drug Conjugate Developers: Distribution by Year of Establishment
Table 26.15 Antibody Drug Conjugate Developers: Distribution by Company Size
Table 26.16 Antibody Drug Conjugate Developers: Distribution by Location of Headquarters
Table 26.17 Most Active Players: Distribution by Number of Therapies
Table 26.18 Seagen: Annual Revenues, 2016 – Q1 2021 (USD Million)
Table 26.19 Roche / Genentech: Annual Revenues, 2016 – 2020 (CHF Million)
Table 26.20 Pfizer: Annual Revenues, 2016 – Q1 2021 (USD Billion)
Table 26.21 AstraZeneca: Annual Revenues, 2016 – Q1 2021 (USD Million)
Table 26.22 Astellas Pharma: Annual Revenues, 2016 – 2020 (JPY Million)
Table 26.23 ImmunoGen: Annual Revenues, 2016 – Q1 2021 (USD Million)
Table 26.24 Daiichi Sankyo: Annual Revenues, 2016 – 2020 (JPY Million)
Table 26.25 Gilead: Annual Revenues, 2016 – 2020 (USD Million)
Table 26.26 AbbVie: Annual Revenues, 2016 – 2020 (USD Billion)
Table 26.27 Bayer: Annual Revenues, 2016 – 2020 (EUR Million)
Table 26.28 KOL Benchmarking: Roots Analysis versus Third Party Scoring
Table 26.29 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2014-2021
Table 26.30 Partnerships and Collaborations: Distribution by Type of Partnership
Table 26.31 Partnerships and Collaborations: Cumulative Trend by Year and Type of Partnership, 2014-2021
Table 26.32 Most Active Players: Distribution by Number of Partnerships
Table 26.33 Partnerships and Collaborations: Regional Distribution
Table 26.34 Funding and Investment Analysis: Cumulative Number of Finding Instances by Year, 2014-2021
Table 26.35 Funding and Investment Analysis: Cumulative Amount Invested by Year, 2014-2021 (USD Million)
Table 26.36 Funding and Investment Analysis: High Value Deals, 2014-2021 (USD Millions)
Table 26.37 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2014-2021
Table 26.38 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2014-2021 (USD Million)
Table 26.39 Most Active Players: Distribution by Number of Funding Instances
Table 26.40 Most Active Players: Distribution by Amount Invested
Table 26.41 Most Active Investors: Distribution by Number of Funding Instances
Table 26.42 Patent Analysis: Distribution by Type of Patent
Table 26.43 Patent Analysis: Cumulative Distribution by Publication Year, 2001-2021
Table 26.44 Patent Analysis: Distribution by Geography
Table 26.45 Patent Analysis: Distribution by Type of Organization
Table 26.46 Leading Industry Players: Distribution by Number of Patents
Table 26.47 Leading Non-Industry Players: Distribution by Number of Patents
Table 26.48 Patent Analysis: Distribution by Patents Age (2001-2021)
Table 26.49 Patent Analysis: Distribution of Patents by Geography (2001-2021)
Table 26.50 Patent Analysis: Valuation Analysis
Table 26.51 Grant Analysis: Cumulative Year-Wise Trend of Grants Awarded, 2016-2021
Table 26.52 Grant Analysis: Distribution by Amount Awarded (USD Million), 2016-2021
Table 26.53 Grant Analysis: Distribution by Administering Institute Center
Table 26.54 Grant Analysis: Distribution by Support Period
Table 26.55 Grant Analysis: Distribution by Administering Institute Center and Support Period
Table 26.56 Grant Analysis: Distribution by Type of Grant Application
Table 26.57 Grant Analysis: Distribution by Purpose of Grant Award
Table 26.58 Grant Analysis: Distribution by Activity Code
Table 26.59 Grant Analysis: Distribution by Study Section Involved
Table 26.60 Popular NIH Departments: Distribution by Number of Grants
Table 26.61 Grant Analysis: Distribution by Type of Recipient Organization
Table 26.62 Most Prominent Program Officers: Distribution by Number of Grants
Table 26.63 Popular Recipient Organization: Distribution by Number of Grants
Table 26.64 Clinical Trial Analysis: Distribution by Trial Status
Table 26.65 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, 2016-2021
Table 26.66 Clinical Trial Analysis: Distribution by Trial Phase
Table 26.67 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status, 2016-2021
Table 26.68 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2016-2021
Table 26.69 Clinical Trial Analysis: Distribution by Study Design
Table 26.70 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 26.71 Most Active Players: Distribution by Number of Registered Trials
Table 26.72 Antibody Drug Conjugates: Distribution by Type of Therapy Evaluation
Table 26.73 Antibody Drug Conjugates Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
Table 26.74 Antibody Drug Conjugates Combination Therapy Clinical Studies: Distribution by Current Trial Status
Table 26.75 Antibody Drug Conjugates Combination Therapy Clinical Studies: Distribution by Trial Date and Type of Combination Therapy
Table 26.76 Antibody Drug Conjugates Combination Therapy Clinical Studies: Distribution by Target Disease Indications and Type of Combination Therapy
Table 26.77 Antibody Drug Conjugates: Relative Share of Individual Processes in the Cost of Production
Table 26.78 Antibody Drug Conjugates: Distribution by Cost of Raw Material Required for the Manufacturing of ADC at Clinical Stage (Without Licensing Fees)
Table 26.79 Antibody Drug Conjugates: Distribution by Cost of Raw Material Required for the Manufacturing of ADC at Clinical Stage (With Licensing Fees)
Table 26.80 ADC Contract Manufacturers: Distribution by Services Offered
Table 26.81 Companion Diagnostics Applicable to Antibody Drug Conjugates: Distribution by Target Antigen
Table 26.82 Companion Diagnostics Applicable to Antibody Drug Conjugates: Distribution by Type of Cancer
Table 26.83 Companion Diagnostics Applicable to Antibody Drug Conjugates: Key Players
Table 26.84 Overall Antibody Drug Conjugates Market, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Billion)
Table 26.85 Antibody Drug Conjugates Market: Distribution by Target Disease Indication, Conservative, Base, and Optimistic Scenarios, 2021, 2025 and 2030 (USD Billion)
Table 26.86 Antibody Drug Conjugates Market: Distribution by Type of Linker, Conservative, Base, and Optimistic Scenarios, 2021, 2025 and 2030 (USD Billion)
Table 26.87 Antibody Drug Conjugates Market: Distribution by Type of Payload, Conservative, Base, and Optimistic Scenarios, 2021, 2025 and 2030 (USD Billion)
Table 26.88 Antibody Drug Conjugates Market: Distribution by Type of Target Antigen, Conservative, Base, and Optimistic Scenarios, 2021, 2025 and 2030 (USD Billion)
Table 26.89 ADC Therapeutics Market: Distribution by Geography, Conservative, Base, and Optimistic Scenarios, 2021, 2025 and 2030 (USD Billion)
Table 26.90 Adcetris Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.91 Kadcyla Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.92 Mylotarg Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.93 Besponsa Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.94 Lumoxiti Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.95 Polivy Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.96 Trodelvy Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.97 Enhertu Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.98 Zynlonta Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.99 Blenrep Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.100 Padcev Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.101 Tisotumab Vedotin Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.102 Mirvetuximab Soravtansine Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.103 ABBV-3373 Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.104 Anetumab Ravtansine Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.105 Disitamab Vedotin Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.106 MRG002 Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.107 Naratuximab Emtansine Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.108 Trastuzumab Duocarmazine Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.109 Tusamitamab Ravtansine Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.110 Cetuximab Sarotalocan Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.111 BA3011 Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 3SBio
  2. 3W Partners
  3. 4BIO Capital
  4. 5AM Ventures
  5. 6 Dimensions Capital
  6. AbbVie
  7. ABL Bio
  8. AbTis
  9. Actinium Pharmaceuticals (ATNM)
  10. Acuta Capital Partners
  11. Adage Capital Management
  12. Adagene
  13. ADC Therapeutics
  14. Adcendo
  15. Advanced Proteome Therapeutics
  16. Advantech
  17. Agensys
  18. Ajinomoto Bio-Pharma
  19. Ally Bridge Group
  20. Alphamab Oncology
  21. Alta Partners
  22. Alteogen
  23. AltruBio
  24. Ambrx
  25. Amgen
  26. Amgen Ventures
  27. Angiex
  28. Antikor Biopharma
  29. Apricot Capital
  30. Aravis
  31. ARCH Venture Partners
  32. Arix Bioscience
  33. Arrowpoint Partners
  34. Asana BioSciences
  35. Astellas Pharma
  36. AstraZeneca
  37. Auven Therapeutics
  38. Avacta
  39. Avalon Ventures
  40. AVICT Global
  41. Avipep Therapeutics
  42. AVROBIO
  43. Bayer
  44. Bayern Kapital
  45. BDC Capital
  46. Beam Therapeutics
  47. BeiGene
  48. BioAtla
  49. BioGeneration Ventures (BGV)
  50. BioMed Valley Discoveries
  51. BioMedPartners
  52. Biotest
  53. BlackRock
  54. BlinkBio
  55. Boehringer Ingelheim 
  56. Boehringer Ingelheim Venture Fund
  57. BOM Capital
  58. Boxer Capital
  59. Boyu Capital
  60. Bregua
  61. BrickBio
  62. BrightGene Bio-Medical Technology
  63. Bristol-Myers Squibb
  64. btov Partners
  65. BVF Partners
  66. Byondis
  67. Calculus Capital
  68. California Institute for Regenerative Medicine (CIRM)
  69. Cambridge Enterprise, University of Cambridge
  70. Canaan Partners
  71. Cancer Prevention and Research Institute of Texas (CPRIT)
  72. Cancer Research Technology (CRT)
  73. Cancer Research UK
  74. Casdin Capital
  75. Catalent
  76. Catalent Biologics
  77. CEL Healthcare
  78. Celgene
  79. Cellerant Therapeutics
  80. Celltrion
  81. Centre for the Commercialization of Antibodies and Biologics (CCAB)
  82. Centrose
  83. Changjinboya
  84. Chengcheng Capital
  85. Chiesi Ventures
  86. Children’s Hospital Los Angeles
  87. China Life Private Equity Investment
  88. China Venture Capital Fund (CVC)
  89. CITIC Private Equity (CPE) 
  90. Clovis Oncology
  91. Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator     (CARB-X)
  92. Coparion
  93. Cormorant Asset Management
  94. Crescendo Biologics
  95. CStone Pharmaceuticals
  96. CTI Life Sciences Fund
  97. CureMeta
  98. CytomX Therapeutics
  99. Daiichi Sankyo
  100. Debiopharm
  101. Decheng Capital
  102. Deerfield Management
  103. Diatheva
  104. dievini Hopp BioTech
  105. Efung Capital
  106. EirGenix
  107. Eli Lilly
  108. EMD Serono
  109. Esperance Pharmaceuticals
  110. Essex Bio-Technology
  111. Eurostars
  112. Eventide
  113. Everest Medicines
  114. Exelixis
  115. Farallon Capital
  116. Femtogenix 
  117. Fidelity Investments
  118. Five Prime Therapeutics
  119. Florida Institute of Technology
  120. Fonds de solidarité FTQ
  121. Foresite Capital
  122. Fortis Therapeutics
  123. Fosun Pharma (formerly Shanghai Fosun Pharmaceutical)
  124. Freenome
  125. GamaMabs Pharma
  126. Genentech
  127. GeneQuantum Healthcare
  128. General Insurance Corporation of India (GIC)
  129. Genmab
  130. Genor Biopharma
  131. GIC
  132. Gilde Healthcare
  133. Gilead Sciences
  134. GlaxoSmithKline
  135. Global Bio-India
  136. Glycotope
  137. Glykos
  138. Glythera
  139. Goodwin Biotechnology
  140. Greater Bay Area Fund
  141. GT Biopharma
  142. Guotai Venture Capital
  143. Gustave Roussy
  144. Hangzhou DAC Biotech
  145. Harbour BioMed
  146. HBM Healthcare Investments
  147. HealthCap
  148. Heidelberg Pharma
  149. Hercules Capital
  150. Heritage Provider Network
  151. High-Tech Gründerfonds
  152. Hillhouse Capital
  153. Hisun Pharmaceuticals
  154. Hofon Capital
  155. Sichuan Hongbo Equity Investment Fund Management
  156. HOPU Investments
  157. Huadong Medicine
  158. Huagai Capital
  159. Hudson Bay Capital Management
  160. Humanwell Healthcare 
  161. Iconic Therapeutics
  162. Iksuda Therapeutics
  163. ImmuneOncia Therapeutics
  164. ImmunoBiochem
  165. ImmunoGen
  166. Immunome
  167. Immunomedics (acquired by Gilead Sciences)
  168. Innate Pharma
  169. Innovate UK
  170. Invenra
  171. Invus
  172. IONTAS
  173. IP Group
  174. iProgen Biotech
  175. Janchor Partners
  176. Janus Henderson Investors
  177. Jazz Pharmaceuticals
  178. Jiangsu Hengrui Pharmaceuticals
  179. JLABS 
  180. Johnson & Johnson Innovation
  181. Johnson Matthey
  182. JT New Century
  183. JX Partners
  184. K2 Investment
  185. Kairos Therapeutics
  186. King Star Capital
  187. Kite Pharma
  188. KLUS Pharma
  189. Lake Bleu Capital
  190. Laurion Capital Management
  191. Legend Capital
  192. LegoChem Biosciences
  193. Levena Biopharma
  194. LifeSci Venture Partners
  195. Lilly Asia Ventures (LAV)
  196. Lilly Ventures
  197. Logos Capital
  198. Loyal Valley Capital
  199. Lumira Capital
  200. MAB Discovery
  201. MabSpace Biosciences
  202. MabVax
  203. MacroGenics
  204. Magenta Therapeutics
  205. Matrix Capital Management
  206. Mayo Clinic
  207. MediaPharma
  208. MedImmune (acquired by AstraZeneca)
  209. Meltwind
  210. Memorial Sloan Kettering Cancer Center
  211. Menarini
  212. Merck
  213. Merck KGaA
  214. Mersana Therapeutics
  215. Millennium Pharmaceuticals
  216. MilliporeSigma
  217. Minomic
  218. Shanghai Miracogen
  219. Mitsubishi Tanabe Pharma
  220. Morphotek (Eisai)
  221. MS Ventures
  222. Multiple Myeloma Research Foundation (MMRF)
  223. Myeloma Investment Fund
  224. NanoValent Pharmaceuticals
  225. National Cancer Institute (NCI)
  226. National Research Council of Canada (NRC)
  227. Navrogen
  228. NBE-Therapeutics
  229. Nerviano Medical Sciences
  230. New Enterprise Associates
  231. Nexthera Capital
  232. Nordic Nanovector
  233. Northeast Securities Prosperity Healthcare Fund
  234. NovImmune
  235. Novo Holdings
  236. NovoCodex Biopharmaceuticals
  237. o2h Ventures
  238. OBI Pharma
  239. OCCIDENT
  240. OGD2 Pharma
  241. Oncolinx
  242. Oncomatryx Biopharma
  243. OPKO Health
  244. OrbiMed Advisors
  245. Oriza Seed Venture Capital
  246. Osage University Partners
  247. Otsuka Pharmaceutical
  248. Overland ADCT BioPharma
  249. Oxford BioTherapeutics (OBT) 
  250. Oxford Finance
  251. PAG
  252. Pappas Capital
  253. Perceptive Advisors
  254. Pfizer
  255. Pfizer Ventures
  256. pH Pharma
  257. PharmAbcine
  258. PharmaMar
  259. Philogen
  260. PICC Capital Equity Investment
  261. Pierre Fabre
  262. PolyTherics
  263. PPF Capital Partners Fund
  264. Puma Biotechnology
  265. Pureos Bioventures
  266. Pyxis
  267. Pyxis Oncology
  268. Qiming Venture Partners
  269. Quantum Leap
  270. RA Capital Management
  271. Rakuten
  272. Rakuten Medical
  273. Ramot
  274. Recepta Biopharma
  275. Redalpine
  276. Redmile Group
  277. Redwood BioScience
  278. Regeneron Pharmaceuticals
  279. RemeGen
  280. The Research Council of Norway
  281. Ridgeback Capital Investments
  282. Roche
  283. Roche Venture Fund
  284. Rock Springs Capital
  285. RTW Investments
  286. Samsara BioCapital
  287. Samsung Biologics
  288. Sanofi
  289. Sarah Cannon Research Institute
  290. SBI Group
  291. Schroder Adveq (acquired by Schroders)
  292. Seagen
  293. Sequoia Capital China
  294. Seventure Partners
  295. Shanghai Pharmaceuticals
  296. Shengda Group
  297. Shenogen Pharma
  298. Siamab Therapeutics
  299. Silicon Valley Bank
  300. Sinopharm Capital
  301. SK
  302. Skyline Ventures
  303. Sofinnova Ventures
  304. Soleus Capital
  305. SOPHiA GENETICS
  306. Sorrento Therapeutics
  307. SOTIO
  308. Springworks
  309. Starling Ventures
  310. Start Codon
  311. Stonebridge Capital
  312. Surveyor Capital
  313. Sutro Biopharma
  314. Suvretta Capital Management
  315. Suzhou Wuzhong Biomedicine Industrial Park Investment
  316. SV Health Investors
  317. Synaffix
  318. SyndicateRoom
  319. Syndivia
  320. Synthon
  321. T. Rowe Price Associates
  322. Taikang Insurance Group
  323. Takeda Oncology
  324. Takeda Pharmaceutical
  325. Takeda Ventures
  326. Tekla Capital Management
  327. Terra Magnum Capital Partners (TMCP)
  328. TF Capital
  329. The Column Group
  330. The Scripps Research Institute
  331. Third Rock Ventures
  332. TOT BIOPHARM
  333. TRIO Pharmaceuticals
  334. Triphase Accelerator
  335. TRITON FUNDS
  336. Tubulis
  337. UCB
  338. University of Copenhagen
  339. University of Wisconsin Carbone Cancer Center (UWCCC) 
  340. Vaccinex
  341. VelosBio (acquired by Merck)
  342. Venrock Healthcare Capital Partners
  343. Vertex Ventures
  344. VI Partners
  345. Vida Ventures
  346. Viking Global Investors
  347. Vir Biotechnology
  348. Visterra
  349. Vivo Capital
  350. Wellington Management
  351. WILD Family Office
  352. Wild Ventures
  353. WS Investments
  354. WuXi AppTec (formerly known as WuXi PharmaTech)
  355. WuXi Biologics
  356. WuXi Healthcare Ventures
  357. WuXi STA
  358. Xintela
  359. Y-Biologics
  360. York University
  361. Ysios Capital
  362. Yuanda China
  363. Yuhan Corporation
  364. Yunfeng Capital
  365. Zhejiang Teruisi Pharmaceutical
  366. Zhejiang University Future Capital
  367. Zheshang Venture Capital
  368. Zymeworks

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com